证券代码：603439 证券简称： 贵州三力 公告编号：2024-087 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司 第四届监事会第七次会议决议公告 一、 监事会会议召开情况 2024 年 11 月 08 日，贵州三力制药股份有限公司（以下简称"贵州三力""公 司"）第四届监事会第七次会议在公司会议室以现场和通讯表决方式召开。本次 会议的会议通知和材料于 2024 年 11 月 01 日以书面及通讯等方式送达所有参会 人员。本次会议应到监事 3 人，实到监事 3 人。本次会议由监事会主席龙静女士 召集和主持，会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的有关规定。 二、监事会会议审议情况 （一）审议通过《关于向 2024 年限制性股票激励计划激励对象授予限制性 股票的议案》 公司于 2024 年 10 月 08 日召开的第四届董事会第六次会议、第四届监事会 第五次会议审议通过了《关于<贵州三力制药股份有限公司 2024 年限制性股票激 励计划（草案）>及其摘要的议案》、《 ...

Investment Rating - The report maintains a "Buy" rating for Guizhou Sanli, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [11]. Core Views - The company has shown significant revenue and profit growth due to the consolidation of Hanfang, with a revenue of 1.45 billion and a net profit of 190 million for Q1-Q3 2024, representing year-on-year growth of 49% and 23% respectively [1][2]. - A stock incentive plan was announced, aiming to boost revenue and develop major products, with performance targets set for the next three years [1][2]. - The company has also announced a dividend plan, share repurchase, and a commitment from the controlling shareholder not to reduce holdings, reflecting confidence in future growth [2]. Financial Performance Summary - For 2024, the company is projected to achieve revenues of 2.407 billion, with a growth rate of 47%, and a net profit of 354 million, reflecting a growth rate of 21% [3][6]. - The earnings per share (EPS) is expected to be 0.86 in 2024, with a price-to-earnings (P/E) ratio of 15.9 [3][6]. - The company’s financial ratios indicate a healthy growth trajectory, with a gross margin of 73.3% and a net margin of 18% for 2023 [6][9].

证券代码：603439 证券简称：贵州三力 公告编号：2024-085 贵州三力制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/13 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 9 月 13 日~2025 年 月 | 9 | 12 | 日 | | 预计回购金额 | 万元~12,000.00 万元 8,000.00 | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 万股 786.93 | | | | | 累计已回购股数占总股本比例 | 1.92% | | | | | 累计已回购金额 | 万元 9,995.44 | | | | | 实际回购价格区间 | 元/股~14.20 元/股 11.82 | | | | 截至 20 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 贵州三力制药股份有限公司（以下简称"公司"）于近日收到公司首次公 开发行A股股票并上市的保荐机构申港证券股份有限公司（以下简称"申港证券"） 送达的《关于变更贵州三力制药股份有限公司首次公开发行股票项目持续督导保 荐代表人的函》，申港证券原委派王东方女士和吴玲玲女士为持续督导期间的保 荐代表人，现因吴玲玲女士工作安排调整原因，不再担任公司的持续督导保荐代 表人。申港证券决定委派牛丽芳女士（简历见附件）接替吴玲玲女士担任公司持 续督导保荐代表人，继续履行相关职责。 本次变更后，持续督导保荐代表人为王东方女士和牛丽芳女士。根据《证券 发行上市保荐业务管理办法》等相关规定，公司首次公开发行A股股票并上市的 持续督导期至2022年12月31日或募集资金使用完毕（以孰晚为止）。公司首次公 开发行A股股票募投项目已于今年结项并将节余募集资金永久补充流动资金（具 体内容详见公司2024年4月27日于上海证券交易所网站（www.sse.com.cn）披露 的《贵州三力制药股份有限公司关于首次公开 ...

Investment Rating - The report maintains a "Recommended" rating for Guizhou Sanli (603439.SH) [1][5] Core Views - The integration of Hanfang has enhanced profits, and the effects of this integration are expected to gradually manifest [4][5] - The company reported a revenue of 1.447 billion yuan for Q3 2024, representing a year-on-year increase of 49.26%, and a net profit of 194 million yuan, up 22.89% [3][4] - The company has initiated a stock repurchase plan and a restricted stock incentive plan, which are expected to benefit long-term development [5] Financial Performance Summary - For Q3 2024, the company achieved a revenue of 527 million yuan, a 55.50% increase year-on-year, and a net profit of 77 million yuan, up 35.17% [3] - The gross margin for the first three quarters of 2024 was 69.28%, down 4.29 percentage points, while the net margin was 13.74%, down 2.50 percentage points [4] - The company forecasts net profits of 354 million yuan, 458 million yuan, and 583 million yuan for 2024, 2025, and 2026, respectively, with a current price-to-earnings ratio of 16.5 times for 2024 [5][6] Revenue and Profit Forecast - Revenue projections for the upcoming years are as follows: 2.333 billion yuan in 2024, 2.930 billion yuan in 2025, and 3.667 billion yuan in 2026, with year-on-year growth rates of 42.7%, 25.6%, and 25.2% respectively [6][11] - Net profit projections are 354 million yuan for 2024, 458 million yuan for 2025, and 583 million yuan for 2026, with year-on-year growth rates of 20.9%, 29.4%, and 27.2% respectively [6][11] Key Financial Ratios - The company’s return on equity (ROE) is projected to be 20.0% in 2024, increasing to 22.1% by 2026 [11] - The debt-to-asset ratio is expected to decrease from 41.5% in 2023 to 27.1% in 2026, indicating improved financial stability [11]

证券代码：603439 证券简称：贵州三力 公告编号：2024-083 贵州三力制药股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 经公司总经理提名，公司董事会审计委员会、董事会提名委员会事先审议通 过，董事会同意聘任郭珂女士（简历附后）为公司财务总监，任期自 2024 年 11 月 1 日起至公司第四届董事会届满之日止。郭珂女士在担任公司财务总监后将不 再继续担任公司副总经理职务。 本议案已经公司第四届董事会审计委员会第三次会议、第四届董事会提名委 1 员会第二次会议审议通过。 具体内容详见同日于上海证券交易所网站（www.sse.com.cn）及指定媒体披 露的《贵州三力制药股份有限公司关于变更公司财务总监及聘任副总经理、补选 董事会部分专门委员会委员及增选公司副董事长的公告》（公告编号：2024-081）。 2024 年 10 月 28 日，贵州三力制药股份有限公司（以下简称"贵州三力"、"公 司"）第四届董事会第七次会议在公司会议室以现场和通讯表决方 ...

Financial Performance - Revenue for Q3 2024 reached ¥526,888,368.01, an increase of 55.50% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥77,072,340.14, reflecting a growth of 35.17% year-on-year[2] - Year-to-date net profit attributable to shareholders reached ¥194,132,141.59, up 22.89% from the previous year[2] - Basic earnings per share for Q3 2024 was ¥0.18, an increase of 28.57% compared to the same period last year[3] - The diluted earnings per share for Q3 2024 was also ¥0.18, reflecting a 28.57% increase year-on-year[3] - Total operating revenue for the first three quarters of 2024 reached CNY 1,447,114,245.43, a significant increase from CNY 969,505,205.34 in the same period of 2023, representing a growth of approximately 49.2%[15] - Net profit for the first three quarters of 2024 was CNY 198,783,556.37, compared to CNY 157,480,116.98 in 2023, reflecting a growth of approximately 26.2%[16] - The total comprehensive income for the first three quarters of 2024 was CNY 198,783,556.37, up from CNY 157,480,116.98 in 2023, indicating a growth of about 26.2%[16] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to ¥3,058,607,480.44, representing a 4.73% increase from the end of the previous year[3] - The company's total liabilities amount to approximately ¥845.71 million, slightly up from ¥839.01 million, indicating a marginal increase[13] - The company's total liabilities amounted to CNY 1,200,910,582.62, slightly down from CNY 1,211,097,697.17 in the previous year[14] - The total equity attributable to shareholders of the parent company increased to CNY 1,602,666,108.48 from CNY 1,470,311,172.51, marking an increase of about 8.9%[14] Cash Flow - The company reported a 51.10% decrease in cash flow from operating activities year-to-date, totaling ¥88,961,699.77[2] - Total cash inflow from operating activities for the first three quarters of 2024 was approximately 1.48 billion RMB, up from 1.07 billion RMB in the same period of 2023, an increase of 37.68%[17] - Net cash flow from operating activities decreased to approximately 88.96 million RMB in 2024 from 181.94 million RMB in 2023, a decline of 51.06%[17] - Cash inflow from investment activities for the first three quarters of 2024 was approximately 85.56 million RMB, down from 168.08 million RMB in 2023, a decrease of 49.05%[18] - Net cash flow from investment activities showed a negative balance of approximately 67.28 million RMB in 2024 compared to a negative 159.26 million RMB in 2023, an improvement of 57.77%[18] - Cash inflow from financing activities increased to approximately 204.20 million RMB in 2024 from 85.00 million RMB in 2023, a significant increase of 140.24%[18] - The company reported a net cash outflow from financing activities of approximately 55.75 million RMB in 2024, compared to a net outflow of 47.74 million RMB in 2023[18] - The ending balance of cash and cash equivalents as of Q3 2024 was approximately 537.30 million RMB, down from 545.77 million RMB in Q3 2023, a decrease of 1.63%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,117, with the largest shareholder holding 40.91% of the shares[8] - The top ten shareholders collectively hold 40.91% of the shares, with the largest individual shareholder owning 167,668,440 shares[10] - The company holds 9,420,200 shares in its repurchase account, representing 2.30% of the total share capital[11] - There are no significant changes in the shareholder structure or voting rights restoration for preferred shareholders during the reporting period[11] Operational Metrics - The increase in revenue and net profit is primarily attributed to sales growth and the consolidation of Hanfang Pharmaceutical[6] - The weighted average return on equity for Q3 2024 was 4.94%, an increase of 0.68 percentage points compared to the previous year[3] - Research and development expenses for the first three quarters of 2024 were CNY 29,839,167.47, compared to CNY 18,471,561.72 in 2023, showing an increase of approximately 61.7%[15] - The company reported a profit margin of approximately 13.7% for the first three quarters of 2024, compared to 16.2% in the same period of 2023[16] - The company's cash flow from operating activities was impacted by increased payments to employees, which rose to approximately 218.43 million RMB from 137.76 million RMB, an increase of 58.54%[17] Non-Recurring Items - Non-recurring gains and losses for the current period included government subsidies amounting to ¥2,581,496.59[4]

证券代码：603439 证券简称： 贵州三力 公告编号：2024-081 贵州三力制药股份有限公司 关于变更公司财务总监及聘任副总经理、 补选董事会部分专门委员会委员 及增选公司副董事长的公告 贵州三力制药股份有限公司（以下简称"公司"）于2024年10月28日，召开 了公司第四届董事会第七次会议，审议通过了《关于变更公司财务总监及聘任副 总经理的议案》、《关于补选董事会部分专门委员会委员的议案》及《关于增选 公司副董事长的议案》，具体情况如下： 一、关于变更公司财务总监及聘任副总经理的情况 因临近退休，张红玉女士提请辞去公司财务总监职务。为确保公司后续财务 工作顺利过渡，辞去上述职务后，张红玉女士将继续担任公司副总经理职务。 本项职务变动自2024年11月1日起生效，至公司第四届董事会届满之日止。 张红玉女士在担任公司财务总监期间恪尽职守、勤勉尽责，公司董事会对张红玉 女士在任职期间为公司发展所作出的重要贡献表示感谢！ 经公司总经理提名，公司董事会审计委员会、董事会提名委员会事先审议通 过，董事会同意聘任郭珂女士（简历附后）为公司财务总监，任期自2024年11 月1日起至公司第四届董事会届满之日止。郭珂女士 ...

证券代码：603439 证券简称：贵州三力 公告编号：2024-080 贵州三力制药股份有限公司 关于控股股东部分股份解除质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 贵州三力制药股份有限公司（以下简称"公司"）控股股东暨实际控制人 张海先生持有公司股份总数 167,668,440 股，占公司总股本的 40.91%。本次解 除质押并再质押后，张海先生累计质押公司股份 69,500,000 股，占其所持有公 司股份总数的 41.45%，占公司总股本的 16.96%。 公司控股股东暨实际控制人张海先生及其一致行动人合计持有公司股份 178,866,387 股，占公司总股本的 43.65%。本次解除质押并再质押后，公司控股 股东及其一致行动人质押股份总数为 69,500,000 股，占控股股东及其一致行动 人合计持有公司股份总数的比例为 38.86%，占公司总股本的比例为 16.96%。 公司于近日接到控股股东暨实际控制人张海先生通知，获悉张海先生将其所 持有的本公司部分股份办理解除质押手续并再质 ...

致：贵州三力制药股份有限公司（以下简称"公司"） 北京市中伦律师事务所 关于贵州三力制药股份有限公司 2024 年第二次临时股东大会的 法律意见书 二〇二四年十月 北京市中伦律师事务所 关于贵州三力制药股份有限公司 2024 年第二次临时股东大会的 法律意见书 北京市中伦律师事务所（以下简称"本所"）接受公司的委托，指派律师出 席并见证公司2024年第二次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》 （以下简称"《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》 （以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律业务执业 规则（试行）》（以下简称"《证券法律业务执业规则》"）等相关法律、行政 法规、规章、规范性文件及《贵州三力制药股份有限公司章程》（以下简称"《公 司章程》"）的规定，就本次会议的召集与召开程序、召集人资格、出席会议人 员资格、会议表决程序及表决结果等事宜，出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所律师仅 ...